425 related articles for article (PubMed ID: 21964785)
21. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
Chuaqui C; Deng Z; Singh J
J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
[TBL] [Abstract][Full Text] [Related]
22. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
23. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
Sheinerman FB; Giraud E; Laoui A
J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
[TBL] [Abstract][Full Text] [Related]
24. Drug discovery and the human kinome: recent trends.
Eglen R; Reisine T
Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
[TBL] [Abstract][Full Text] [Related]
25. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
26. High-throughput virtual screening using quantum mechanical probes: discovery of selective kinase inhibitors.
Zhou T; Caflisch A
ChemMedChem; 2010 Jul; 5(7):1007-14. PubMed ID: 20540063
[TBL] [Abstract][Full Text] [Related]
27. Doing more than just the structure-structural genomics in kinase drug discovery.
Marsden BD; Knapp S
Curr Opin Chem Biol; 2008 Feb; 12(1):40-5. PubMed ID: 18267130
[TBL] [Abstract][Full Text] [Related]
28. An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors.
Chopra P; Nanda K; Chatterjee M; Bajpai M; Dastidar SG; Ray A
Anal Biochem; 2008 Sep; 380(1):143-5. PubMed ID: 18570885
[TBL] [Abstract][Full Text] [Related]
29. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
Martin E; Mukherjee P; Sullivan D; Jansen J
J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
[TBL] [Abstract][Full Text] [Related]
30. Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode.
Kettle JG; Ward RA
J Chem Inf Model; 2010 Apr; 50(4):525-33. PubMed ID: 20141221
[TBL] [Abstract][Full Text] [Related]
31. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
[TBL] [Abstract][Full Text] [Related]
32. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
33. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.
Gong LL; Fang LH; Peng JH; Liu AL; Du GH
J Biotechnol; 2010 Feb; 145(3):295-303. PubMed ID: 19963024
[TBL] [Abstract][Full Text] [Related]
34. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.
Kashem MA; Nelson RM; Yingling JD; Pullen SS; Prokopowicz AS; Jones JW; Wolak JP; Rogers GR; Morelock MM; Snow RJ; Homon CA; Jakes S
J Biomol Screen; 2007 Feb; 12(1):70-83. PubMed ID: 17166826
[TBL] [Abstract][Full Text] [Related]
35. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
[No Abstract] [Full Text] [Related]
36. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.
Uitdehaag JC; Sünnen CM; van Doornmalen AM; de Rouw N; Oubrie A; Azevedo R; Ziebell M; Nickbarg E; Karstens WJ; Ruygrok S
J Biomol Screen; 2011 Oct; 16(9):1007-17. PubMed ID: 21873591
[TBL] [Abstract][Full Text] [Related]
37. Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors.
Akritopoulou-Zanze I; Hajduk PJ
Drug Discov Today; 2009 Mar; 14(5-6):291-7. PubMed ID: 19121409
[TBL] [Abstract][Full Text] [Related]
38. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
Fang Z; Grütter C; Rauh D
ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
[TBL] [Abstract][Full Text] [Related]
39. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
40. Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors.
Lo MC; Ngo R; Dai K; Li C; Liang L; Lee J; Emkey R; Eksterowicz J; Ventura M; Young SW; Xiao SH
Anal Biochem; 2012 Feb; 421(2):368-77. PubMed ID: 22056947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
